Ver­tex ex­ecs whip up a cheer from the an­a­lysts af­ter hedg­ing their bet by pick­ing their two top triples for PhI­II

Ver­tex mapped out its late-stage strat­e­gy for a new triple ther­a­py for cys­tic fi­bro­sis on Wednes­day evening, earn­ing con­sid­er­able ap­plause from an ap­pre­cia­tive group of an­a­lysts cov­er­ing the biotech.

The biotech’s $VRTX ex­ec­u­tive team has stoked block­buster hopes around these com­bi­na­tion stud­ies, key to their plan to broad­en the scope of pa­tients they can cov­er, and they did their best to keep ex­pec­ta­tions high as ri­vals look to carve in­to the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.